Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
A critical aspect of real-world functioning following kidney transplantation involves how
adherent individuals are to their medication regimens. Regardless of the possible dangers of
failing to adhere to anti-rejection medications, such as increased graft rejection, studies
have reported rates of non-adherence at almost 50% following renal transplant.
The Cognitive Aging Laboratory under the direction of Dr. Wendy Thornton, at Simon Fraser
University, has previously identified relationships between several potentially important
cognitive and psychosocial variables, and self-reported medication adherence in renal
transplant recipients, including depressive symptoms, as well as everyday and traditional
cognitive functioning [4]. The possibility that changes in dosing regimens for a given
medication may have an additional impact on medication adherence presents an important issue
worth further exploration.
The current study will allow for more thorough delineation of the roles of psychosocial and
cognitive predictors of adherence with state-of-the-art monitoring techniques. In addition,
the investigators will assess whether different dosing formulations of tacrolimus impact
adherence behaviors in renal transplant recipients.
The proposed research has two primary aims to examine:
1. To examine the role of cognitive and psychosocial variables in predicting medication
adherence in renal transplant recipients.
2. To examine whether different formulations of tacrolimus (once per day dosing versus
twice per day dosing) will impact medication adherence in renal transplant recipients.
Phase:
Phase 4
Details
Lead Sponsor:
University of British Columbia
Collaborators:
Astellas Pharma Canada, Inc. Simon Fraser University